Revenues increased 27% year over year to $968 thousand in 4Q25. Operating loss increased 17% year over year, primarily due to higher selling expenses directly related to increased sales volume and ...
NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results